Your Ligase Matters for Scalable RNA Manufacturing

Overview

As demand for siRNA therapies accelerates, RNAi developers are re‑evaluating traditional solid‑phase oligonucleotide synthesis (SPOS) in favor of ligation‑based approaches that offer greater efficiency, flexibility, and scalability—especially for chemically modified constructs.

This 10-minute session examines how superior engineered ligases and advanced ligation technologies are reshaping RNA manufacturing workflows.

Abstract

RNAi companies are evaluating ligation‑based approaches for siRNA generation due to their inherent advantages in efficiency, scalability, and compatibility with chemical modifications compared to sequential synthesis using SPOS. Superior ligation technologies streamline downstream processing by enhancing efficiency, ensuring reproducibility, and reducing purification steps. In this session, we’ll show how advanced enzyme engineering, process optimization, and integrated manufacturing powered by machine learning deliver industry‑leading solutions for ligation processes.

Key Takeaways

• Why ligation is gaining momentum as a scalable alternative to SPOS
• Why your ligase matters
  • How highly optimized enzymes improve ligation efficiency and reproducibility
• The role of ligation in reducing purification burden and process complexity
• How data‑driven optimization accelerates manufacturing performance

Who Should Watch

RNAi innovators, manufacturing and process development teams, and technical leaders evaluating next‑generation siRNA production strategies.